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MicroRNAs (miRNAs) are key post transcriptional regulators of their multiple target genes.
However, the detailed profile of miRNA expression in Parkinson’s disease, the second
most common neurodegenerative disease worldwide and the first motor disorder has not
been charted yet. Here, we report comprehensive miRNA profiling by next-generation
small-RNA sequencing, combined with targets inspection by splice-junction and exon
arrays interrogating leukocyte RNA in Parkinson’s disease patients before and after
deep brain stimulation (DBS) treatment and of matched healthy control volunteers (HC).
RNA-Seq analysis identified 254 miRNAs and 79 passenger strand forms as expressed in
blood leukocytes, 16 of which were modified in patients pre-treatment as compared to HC.
11 miRNAs were modified following brain stimulation 5 of which were changed inversely
to the disease induced changes. Stimulation cessation further induced changes in 11
miRNAs. Transcript isoform abundance analysis yielded 332 changed isoforms in patients
compared to HC, which classified brain transcriptomes of 47 PD and control independent
microarrays. Functional enrichment analysis highlighted mitochondrion organization. DBS
induced 155 splice changes, enriched in ubiquitin homeostasis. Cellular composition
analysis revealed immune cell activity pre and post treatment. Overall, 217 disease and
74 treatment alternative isoforms were predictably targeted by modified miRNAs within
both 3′ and 5′ untranslated ends and coding sequence sites. The stimulation-induced
network sustained 4 miRNAs and 7 transcripts of the disease network. We believe that
the presented dynamic networks provide a novel avenue for identifying disease and
treatment-related therapeutic targets. Furthermore, the identification of these networks
is a major step forward in the road for understanding the molecular basis for neurological
and neurodegenerative diseases and assessment of the impact of brain stimulation on
human diseases.
Keywords: deep brain stimulation, high throughput sequencing, leukocytes, miRNAs, Parkinson’s disease, splice
junction microarrays, substantia nigra
INTRODUCTION
Parkinson’s disease (PD) is the second most prevalent neurode-
generative disease worldwide and the first movement disorder. PD
is mainly expressed in progressive, deliberating motor symptoms,
initiating with tremor at rest, slowness of movement and rigidity
which develops into flexed posture, loss of postural reflexes and a
freezing phenomenon (Fahn and Elton, 1987). Notably, the car-
dinal motor symptoms appear only years after initiation of the
disease process. As the disease presents other central signs such
as depression, sleep disorders (Bernal-Pacheco et al., 2012) and
dementia (Goldman and Litvan, 2011) as well as peripheral symp-
toms (e.g., digestive and olfactory impairments) (Braak and Del
Tredici, 2008), it is becoming increasingly clear that PD is not a
pure motor disorder. In fact, it may initiate many years prior to
the appearance of the motor symptoms (Hawkes et al., 2010).
However, current methods do not allow early or accurate diag-
nosis and moreover, the genes and mechanisms that lead to the
massive dopaminergic neuronal loss in the damaged PD brain
are still largely obscure. The growing prevalence of PD worldwide
introduces a strong incentive to find both disease biomarkers and
future therapeutic targets.
MicroRNAs (miRNAs) are key post transcriptional regulators.
Since their discovery 20 years ago (Lee et al., 1993), it has been
well demonstrated that they play essential roles in development
(Reinhart et al., 2000) as well as in human diseases, for example
in cancer (Mraz et al., 2009; Li et al., 2013; Pu et al., 2013), as well
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as Alzheimer’s disease and other central nervous system disorders
(Maes et al., 2009). A growing body of evidence now suggests
that peripheral miRNA changes may co-occur with the onset of
PD (Doxakis, 2010; Martins et al., 2011). MiRNAs mediate post-
transcriptional regulation of protein-coding genes by primarily
binding to short sequence motifs found typically in the 3′ un-
translated region of target mRNAs. Depending on the degree
of sequence complementation, this leads to translational inhibi-
tion, mRNA destabilization or degradation. Since their discovery,
miRNAs have emerged as crucial regulators of gene expression,
and a single miRNA can concurrently regulate hundreds of target
mRNAs. However, despite their biologic importance, determining
global miRNA profiles and functional miRNA-target interactions
remained a major challenge. Correspondingly, so far only about
20% of the known human miRNAs were found as constituting
biological networks of functionally-associated molecules (Satoh
and Tabunoki, 2011).
PD-related miRNAs have been characterized in midbrain
dopaminergic neurons (Kim et al., 2007; Minones-Moyano et al.,
2011), and were found to post-transcriptionally regulate the key
PD genes LRRK2 (Gehrke et al., 2010) and SNCA (Doxakis,
2010). Also, down-regulation of miR-34b/c was found to mod-
ulate mitochondrial function in PD (Martins et al., 2011) and
deletion of hsa-let-7 caused toxic effects similar to those of
pathogenic LRRK2 (Gehrke et al., 2010) in a Drosophila PD
model. However, post-mortem brain tissue is not readily acces-
sible, and entails RNA quality concerns (Atz et al., 2007). Blood
leukocytes, however, are readily obtained, and the RNA can be
obtained at high quality from them. Recently, miRNAs were char-
acterized in whole blood of PD patients (Martins et al., 2011) by
microarrays and quantitative real time PCR (Margis and Rieder,
2011). RNA-Seq provides an unbiased, high resolution, accurate
means for profiling miRNAs (Pritchard et al., 2012) and thus
for investigating the miRNA mediated pathogenesis of complex
diseases such as PD. Purported advantages of small RNA sequenc-
ing for this purpose include generation of data unlimited by
genome annotations or probe affinities. Analyses of genome-wide
small RNA transcriptome provide an accurate and comprehensive
approach of globally characterizing miRNA expression in disease
under different conditions. Yet, the global profile of miRNAs was
not characterized yet by comprehensive RNA high throughput
sequencing of PD blood cells.
Alternative splicing (AS) dramatically increases the complexity
of the human transcriptome. Recent studies identified possi-
ble interactions between miRNAs and spliced targets (Salomonis
et al., 2010; Irimia and Blencowe, 2012). Yet, while gene-
expression changes have been characterized in PD blood cells
using conventional microarrays (Scherzer et al., 2007; Soreq et al.,
2008), such studies are blinded to alternative isoform regula-
tion, which has been associated with at least 95% of the human
genes (Pan et al., 2008). Deep brain stimulation (DBS) treat-
ment dramatically improves the debilitating PDmotor symptoms
which are the cardinal disease symptoms (Bergman et al., 1990;
Kingwell, 2011). Recently, we found disease-related transcription
changes in PD leukocytes and demonstrated that DBS neuro-
surgery largely reversed the observed transcriptional changes
(Soreq et al., 2012b). We have identified that a large number
of predicted miRNA binding sites located in alternative exon
regions.
Here, we performed a comparative miRNA, splicing and gene
expression analysis of PD patients’ blood leukocytes pre- and
post-DBS with the electrical stimulus being on and following 1 h
of stimulation cessation using high throughput RNA sequenc-
ing in conjunction with exon and splice junction microarrays of
the same cells. Along with these samples, mRNA samples from
matched healthy control volunteers were analysed.
We found significant differences in miRNA expression levels in
PD, partially reversed by DBS, which co-occurred with high con-
fidence changes in gene isoform expression levels and cell lineage
composition. Our findings provide new insights for the molecular
mechanisms underlying peripheral reactions to neurological and
neurodegenerative diseases and opening new avenues for future
development of both new diagnostic and therapeutic tools. We
provide these data sets and analyses as a resource for under-
standing miRNA expression and splicing in Parkinson’s patient’s
leukocytes pre- and post-treatment.
MATERIALS AND METHODS
This study was authorized and approved by the Ethics commit-
tee of the human review board (Hadassah University Hospital,
Ein-Kerem, approval number 07.09.07-6) in accordance with the
Declaration of Helsinki principles. Following oral agreement all
participants signed informed consent prior to inclusion in the
study.
PATIENT RECRUITMENT, DBS NEUROSURGERY AND CLINICAL
EVALUATION
Overall, seven PDmale patients nominated for bilateral STN-DBS
neurosurgery and six healthy age-matched male controls healthy
control volunteers (HC) were recruited to the study. Clinical
description appears under (Soreq et al., 2012b). Briefly, volun-
teers were assessed for their clinical background and state and
fulfilled detailed medical history questionnaires. Patients with
other medical conditions were excluded, including depression
and past and current DSM Axis I and II psychological disorders
(SM), chronic inflammatory disease, coagulation irregularities,
previous malignancies or cardiac events, or any surgical proce-
dure up to one year pre-DBS. All patients went through bilateral
STN-DBS electrode implantation (Medtronics, USA) and were
under dopamine replacement therapy (DRT) both pre- and post-
DBS (on significantly reduced dosage post-DBS both on and
off stimulation), the last medication administered at least 5 h
pre-sampling. Patients further exhibited similar total white and
red blood cell counts pre- and post-DBS. Blood samples were
collected from each patient at three time points: (1) one day
pre-DBS upon hospitalization, with medication; (2) post-DBS
(range 6–18 weeks), when reaching optimal clinical state as eval-
uated by a neurologist and on a lower DRT dose, ON stimulus
and (3) OFF stimulus, following 1 h while being OFF electri-
cal stimulation (counted from stage 2). The clinical severity
of disease symptoms was assessed by a neurologist for Unified
PD Rating Scale (UPDRS-III) (Fahn and Elton, 1987) section
3 (motor section) in the tested stated (pre-DBS, post-DBS on
and off stimulation). Controls were recruited among Hadassah
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hospital staff and researchers at the Edmond J. Safra Campus
(Jerusalem). Exclusion criteria for the HC volunteers included
smoking, chronic inflammatory diseases, drug or alcohol use,
major depression, previous cardiac events and past year hospi-
talizations. The only group of other control volunteers that was
included in this study is of healthy control volunteers, as samples
from “sham” operated healthy (or patient) volunteers cannot be
obtained or authorized by ethics committee. However, in addi-
tion to the healthy controls, we tested the leukocyte RNA from
PD patients post-DBS also following 1 h of electrical stimulation
cessation, to enable discrimination of the electrical stimulation
effect from the effect of the presence of the stimulator in the brain
per-se.
BLOOD SAMPLE COLLECTION AND RNA EXTRACTION
Blood collection was conducted between 10AM–14PM. Collected
venous blood (9ml blood using 4.5ml EDTA (anti-coagulant
tubes) was immediately filtered using the LeukoLock fractiona-
tion and stabilization kit™ (Ambion, Applied Biosystems, Inc.,
Foster City, CA) and incubated in RNALater (Ambion). Stabilized
filters and serum samples were stored at −80◦C. RNA extraction
followed the manufacturers’ alternative protocol instructions.
Briefly, cells were flushed (TRI-Reagent™, Ambion) into 1-
bromo-3-chloropropane-(BCP) containing 15ml tubes and cen-
trifuged. 0.5 and 1.25 volume water and ethanol were added
to the aqueous phase. Samples were filtered through spin car-
tridges, stored in pre-heated 150µl EDTA; RNA was quantified
and examined on Bioanalyzer 2100 (Agilent, Santa Clara, CA,
USA) and frozen in −80◦C.
RNA-Seq SREK LIBRARY PREPARATION AND SEQUENCING
Libraries for next generation sequencing (NGS) were prepared
from total leukocyte RNA with the manufacturers’ SREK (Small
RNA Expression Kit) protocol (Applied Biosystems, Foster City,
CA, USA). A total of 12 libraries were prepared: from RNA of
blood leukocytes from three healthy volunteers and three PD
patients in three states (pre-DBS, post-DBS on stimulation and
following 1 h of stimulation cessation). The DNA Libraries were
tested using a DNA 1000 Lab Chip on Bioanalyzer 2100. Briefly,
the total RNA samples were hybridized with AdaptorMix A which
is a set of oligonucleotides with a single-stranded degenerate
sequence at one end and a defined sequence required for SOLiD
sequencing at the other end. The Adaptor Mix A constrains
the orientation of the RNA in the ligation reaction such that
hybridization with it yields template for SOLiD sequencing from
the 5′ end of the sense strand. After hybridization, the adaptors
are ligated to the small RNA molecules using Ligation Enzyme
Mix, which is a mixture of an RNA Ligase and other components.
Ligation requires an RNA molecule with a 5′-monophosphate
and a 3′-hydroxyl end; therefore, most small RNAs can partici-
pate in this reaction, and intact mRNA molecules with a 5′ cap
structure are excluded. Next, the small RNA population with lig-
ated adaptors of each sample was reverse transcribed, to generate
cDNA libraries. Treatment with RNase H followed, to digest the
RNA from RNA/cDNA duplexes and to reduce the concentra-
tion of unligated adaptors and adaptor by-products. The cDNA
libraries were amplified using bar-coded primer sets and 15–18
cycles of PCR. The amplified cDNA libraries were cleaned up
and size selected from gel—PCR products ∼105–150 bp were
isolated, corresponding to inserts derived from the small RNA
population. These contained each 90 base pairs of primers and
adapter sequences. The amplified cDNA libraries generated with
the SOLiD Small RNA Expression Kit were thereafter ready for
attachment to beads at the emulsion PCR step of the SOLiD
sample preparation workflow. The slides were analyzed on a
SOLiD system V3.5 (Applied Biosystems). Applied Biosystems
SOLiD sequencer generated 50-base read sequences as.csfasta
files and the corresponding quality control (.qual) and statistic
(.stat) files.
MAPPING TO miRBase AND TO HUMAN REFERENCE GENOME
A total of 166,746,207 sequencing reads were obtained. All the
reads (50 bp long) were subjected to trimming of the tag end
terminal base pairs to remove these 15 bases. The trimmed
(35 bases) reads were subjected to further trimming of the P1 start
adapter as well as the SOLiD miRNA reverse primer sequences
using CLC genomics workbench V4.0 [CLC bio, Cambridge, MA
(Sakharkar et al., 2004a)] through local Smith–Watermann align-
ment. Overall, 50.92% of the reads contained adapter sequence
and/or the SOLiD small RNA reverse primer. The 5′ termi-
nal nucleotide was removed as well. This left 71,939,833 reads
(average length of 21 bases). The minimum sampling count
threshold was set to 1. The remaining reads obtained from each
patient’s library were first aligned against the human miRNA
genome (miRBase release 15, which contained 940 Homo sapi-
ens sequences). On average, 55% (range 44.9–61.3%) of the
sequences of all libraries were mapped (Figure S1) and 50.94%
(range 43.8–54.8%) of miRBase genes were detected (Figure S1).
Of the mapped reads, on average 42.03% (range 39.6–45.9%) had
perfect match to the aligned genes, 45.16% (range 42.5–55.3%)-
one mismatch, 12.6% (range 0–18.6%)-2 mismatches and 0.18%
(range 0.1–0.6%)-3 mismatches (Figure S1).
The full count information obtained from the alignment
results is given under Tables S4 and S5. Through the annota-
tion and merge counts, only reads longer than 15 bases were
analyzed. Match parameters included for mature length vari-
ants (IsomiRs)-additional 2 upstream and downstream bases, and
2 missing upstream and downstream bases. Alignment settings
were not conducted on the color space. This allowed detection of
mismatches up to the maximal allowed by the software (of 3 mis-
matches instead of 2). Annotated samples were grouped by both
precursor and mature sequence identity.
Mapping to another repository of reference human genome
database (Ambion, life technologies) which included 764
sequences of snoRNAs, tRNA, SINE/ALU sequences, LINEs and
spliceosomal U genes (such as U1) yielded mapping to 293.3
(38.37%) filter database sequences on average across libraries.
Only 151,136.8 (3.16%) reads of these that were not mapped to
miRBase were mapped against this repository. Of them, 60.88%
(range 42.2–68.9%) exhibited perfect match to the reference
sequences, 30.94% (range 25.4–41.2%) with 1 mismatch, 6.24
(2.1–13.4%)-2 mismatches and 1.94% (0.5–3.3%)-3 mismatches
(Figure S1). An average of 486 miRNAs per sample (range:
436–515) were detected in the analyzed libraries (Figures S2A–E:
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selected examples, full raw digital count quantification under
Tables S4 and S5).
DIFFERENTIAL EXPRESSION ANALYSIS OF NEXT GENERATION
SEQUENCING DETECTED miRNAs
Overall, a total of 335 mature and 79 mature-star (mature 3′/5′
forms) that exhibited count of at least 1 per million reads
in at least one sample were analyzed for differential expres-
sion between the different experimental conditions. Differential
expression analysis of the miRNAs was conducted using the
Bioconductor R package biocLite. The EdgeR (Robinson et al.,
2010) and BaySeq (Hardcastle and Kelly, 2010) components were
used for differential expression. 251 miRNAs were detected in
all the samples, but the statistical methodologies applied allowed
to analyze the detected miRNAs that presented count of at least
1 per million reads in at least one sample using adjacent sta-
tistical approach, to avoid false negative results. First, a com-
bined data matrix of all the miRNAs detected in any of the
samples was created. Then, the detected miRNAs were filtered
for low count values such that only these with count ≥ 1 in
at least 3 of the 12 libraries remained and 351 miRNAs were
analyzed.
AFFYMETRIX HJAY SPLICE JUNCTION MICROARRAY HYBRIDIZATIONS
AND DATA PRE-PROCESSING
The Affymetrix human junction arrays (HJAY) were obtained
through collaboration with the EURASNET consortium and
were used to assess genome-wide changes in exon and junction
expression. Briefly, these microarrays interrogate 335,663 human
transcripts from ∼25,000 Ensembl genes, 260,488 junctions and
360,569 exons. Using the program AltAnalyze, probe set level
RMA [17] expression and DAGB p-values were obtained by call-
ing Affymetrix Power Tools (APT) [17]. From this probe set-level
data, sample gene expression values were calculated from the
mean intensity of constitutive annotated exon and junction probe
sets in AltAnalyze.
HJAY MICROARRAY PROFILING, DATABASE CONSTRUCTION AND
ANALYSIS
HJAY profiling of blood leukocytes was conducted using
exon array pre-prepared hybridization samples and Gene-Chip
Whole Transcript Sense target Labeling assay kit (Affymetrix),
as per manufacturers’ instructions. The high-density HJAYs
(Affymetrix) were washed and stained with streptavidin-
phycoerythrin and signal amplification was done using a
biotinylated anti-streptavidin antibody. The microarrays were
scanned on an Affymetrix GeneChip Scanner 3000 7G scan-
ner, according to the Affymetrix GeneChip Whole Transcript
Sense Target Labeling Assay protocol for the GeneChip Exon
1.0 ST array (Lapuk et al., 2010). A total of 12 microarray sam-
ples were obtained. AltAnalyze probe set-to-exon associations
were obtained by matching the annotated exon sequences (two
exons for each junction probe sets) provided by Affymetrix
to the reference Ensembl genome (version 62) for Affymetrix
annotated gene symbols. In cases where probe sets aligned
to an intron, a novel exon annotation indicating the rela-
tive intron position was assigned. Alternative exons, junctions,
reciprocal probe sets and event-annotations (e.g., alternative cas-
sette exon, alternative promoter) were obtained by comparing
the exon-structure of mRNAs from Ensembl, the UCSC genome
database and novel junctions assayed by the HJAY array, as
previously described (Salomonis et al., 2010). Linear regres-
sion analysis was employed by an updated version of AltAnalyze
to detect AS with a fold change of 2. P < 0.05 were con-
sidered significant. Additional methods details are provided at
http://www.altanalyze.org/help_main.htm.
FUNCTIONAL PREDICTION ANALYSIS OF THE HJAY DETECTED SPLICED
TRANSCRIPTS
Each detected alternative event or alternative promoter selec-
tion (e.g., cassette exon, alternative 3′ end, alternative 5′ end,
intron retention, bleeding exon, alternative C-terminal exon) or
alternative promoter (alternative N-terminal exon or alternative
promoter) of a pair of reciprocal junctions detected by the linear
regression analysis was examined for putative protein domains or
motifs and for miRNA binding sites. Alternative event annota-
tions were obtained from both from Ensembl and UCSC Genome
Browser databases as previously described for AltAnalyze version
1.0 (Salomonis et al., 2009).
FUNCTIONAL ENRICHMENT ANALYSIS OF THE HJAY DETECTED
SPLICED TRANSCRIPTS
Functional post-hoc analysis of the alternative isoforms detected
by linear regression analysis conducted for each comparison
(e.g., patients pre-treatment as compared with controls) using
Gene Ontology (GO) Elite (Zambon et al., 2012) was called
directly from the adopted AltAnalyze version using Ensembl
database. Genes cut-off parameters included minimal 2-fold
change; and t-test raw P-value< 0.05 with minimum number of
3 changed genes defined. GO terms (Ashburner et al., 2000) and
WikiPathways (Pico et al., 2008) were ranked by a combination
of z-score (cut-off: 1.96) and gene number. Over-representation
analysis (ORA) was conducted with 2000 permutations.
BRAIN TRANSCRIPTOME MICROARRAY ANALYSIS
Raw expression data was obtained from the GEOdataset GSE8397
[citation: (Moran et al., 2006)], where Affymetrix HG_U133 array
sets were used to determine the whole genome transcription pro-
file of clinically documented and neuropathologically confirmed
cases of sporadic Parkinson’s disease as well as controls (and
overall 47 samples). The .CEL files were normalized by sketch
normalization and the expression of the 22,283 interrogated
probe-sets (including 68 microarray internal control prone-sets)
was quantified from 506,944 probes using the Probe Logarithmic
Intensity Error estimation (PLIER) method (Affymetrix)
while considering mismatch probes (Irizarry et al., 2003)
(PLIER-MM).
EXON MICROARRAYS HYBRIDIZATION AND INITIAL PRE-PROCESSING
1µg of total RNA was labeled using the Affymetrix exon array
using whole transcripts sense targeting labeling assay according to
the manufacturers’ instructions; cDNA samples were hybridized
to GeneChip® Exon_1.0_ST_Array (Affymetrix, Santa Clara, CA,
USA) microarrays, and results were scanned (GeneChip scan-
ner 30007G, 27 CEL files). Hybridizations were conducted in
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7 batches. To prevent possible batch effect, each microarray
hybridization included samples of patients from all experimental
stages (pre, post-DBS on stimulation and post-DBS off stim-
ulation) by random sampling. Quality assurance, normaliza-
tion (quantile) and probe set summation (DABG iter-PLIER)
were conducted using expression console (EC) 1.0 (Affymetrix,
Santa Clara, CA). Only core level probe sets (n = 284.241) were
included to summarize probe set level expression for 22,011 exon
array transcript clusters (iter-PLIER, EC). Filtering out transcript
clusters with no annotated gene symbols maintained 17,658 of
22,011 transcripts.
CELLULAR LINEAGE ANALYSIS OF THE EXON MICROARRAYS DATA
To identify cellular composition, the new module of AltAnalyze,
LineageProfiler, was used. To derive correlation scores to dif-
ferent cell types and tissues (lineages), a database reflecting the
most specifically-expressed genes or exons present in each par-
ticular lineage, relative to all lineages types examined (ranging
from 50 to 150), was created. The resulting database was a small
subset of the original, containing the most informative markers.
The exon microarrays RNA-profile expression data of patients in
three states (pre-DBS, post-DBS on and following 1 h of electri-
cal stimulation cessation-off stimulus) and HC volunteers was
compared to the profile of each lineage only for these markers
to derive correlation coefficients and resulting Z scores based on
the distribution of values for each user RNA-profile. Z scores
to each lineage were calculated from the distribution of Pearson
correlation coefficients, specifically for each sample or condition
analyzed. Lineage differences between conditions were specifically
evaluated via the AltAnalyze GO-Elite module using the database
of lineage specific markers for examined differentially expressed
genes. The results were visualized as association scores at the level
of hierarchically clustered cell types and curated lineage networks.
miRNA: TARGET PREDICTIONS
Prediction of target gene sites for the miRNAs that exhibited
differential expression in PD patients compared to control vol-
unteers was conducted using the miRWalk repository which
combines prediction data from 8 different prediction programs
and adds inspection of all the gene regions including 5′ UTR
and coding regions (Dweep et al., 2011). The analysis was con-
ducted through a construction of a local MySQL database based
on these predictions. For each miRNA that was detected as differ-
entially expressed in the deep transcriptome of patients compared
to control volunteers and post compared to pre-DBS, all the
predicted targets were searched for and were filtered to these
that were detected as alternatively spliced in the human junction
microarrays for the corresponding tested condition. The final net-
work of miRNA-spliced targets was analyzed and created through
Cytoscape (Smoot et al., 2011).
ACCESSION CODES
All the data discussed in this publication have been deposited in
NCBI’s Gene Expression Omnibus (Edgar et al., 2002):
(1) High throughput SOLiD small RNA sequencing:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=btahlk
cwcuyyyvy&acc=GSE40915
(2) Splice junction microarrays: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token=hhmvrgcsyyciexi&acc=GSE37591
(3) Exon microarrays: http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE23676
RESULTS
DIFFERENTIAL EXPRESSION OF miRNAs IN PD COMPARED TO
HEALTHY VOLUNTEERS
To delineate the expression of miRNAs in PD peripheral blood
leukocytes, we employed SOLiD high throughput sequenc-
ing on small RNAs from peripheral blood leukocytes of PD
patients followed by alignment to miRBase. The samples were
obtained from three PD patients prior to DBS treatment, and
upon symptoms stabilization following DBS neurosurgery, both
on stimulation and following 1 hour off-electrical stimula-
tion and as compared with matched healthy volunteers (clin-
ical information under Table S1). The study design and over-
all analysis flow are given under Figure 1. The full mapping
information and reads count are given under Tables S2 and
S4. Alignment to miRNABase detected 44.9–61.3% annotated
reads (an average detection of 54.67% reads of each library)
constituting 43.8–54.8% of miRBase (Figure S1 and Table S2).
For comparison, we also aligned all the sequenced libraries
against a reference database which contained 764 human filter
sequences of other non-coding RNAs including snoRNAs, scR-
NAs, 5S_RNAs, tRNAs, SINE and ALU repeats, LINEs, spliceo-
somal U sequences (number 1,2,3,4,5,6,8,13,14, and 17) and
snRNAs. These alignments yielded an average of 8.9% aligned
reads of the total number of reads (with a minimum of 0.2%
and a maximum of 3.16%) (Table S3). The raw read counts
of all the detected miRNA and miRNA∗ (also termed 3′/5′)
mature forms (given under Tables S4, S5 and Figures S2A–E)
were filtered to include only those presenting at least 1 reads
per million base pairs in at least three samples. Thus, 254
miRNAs, 2 recent miRNA-candidates which are highly likely
tRNA fragments and 79 passenger strand miRNAs 3′/5′ forms
(miRNA∗) were analyzed (altogether 334). At the technical level,
count data was discrete and skewed and was hence not well
approximated by a normal distribution. To account for this,
we applied a test based on the negative binomial distribution
(a generalization of the Poisson model that recaptures biolog-
ical variance correctly) (Robinson and Smyth, 2008). This test
can effectively reflect the sample properties and detect differ-
ential expression. A linear modeling approach was applied for
calculating fold changes and estimating standard errors, and
was followed by an empirical Bayes smoothing (which pro-
vides more stable results for small sample sized data sets) to
moderate the standard errors [16]. Also, sequenced libraries
differ in the number of expressed transcripts. This fact could
skew the differential expression calls due to over- and under-
sampling (Robinson and Oshlack, 2010). To overcome this
difficulty, we estimated tag-wise common dispersion to com-
pute normalization factors for each library while accounting
for library size. The common dispersion values enabled esti-
mation of the bias using an empirical approach and were built
into the library size. The computed concentrations were fur-
ther subjected to an exact test to detect the top differentially
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FIGURE 1 | Experimental design and analysis flow. (A) RNA was
prepared from filtered blood leukocytes isolated from whole blood
samples of PD patients 1 day prior to DBS (PD), and post-DBS upon
clinical stabilization, both on (DBS-ON) and following 1 h off electrical
stimulation (DBS-OFF). Age- and gender-matched male healthy volunteers
served as a control group (HC). Small RNA libraries were prepared using
a Small RNA Expression Kit (SREK) and constructed according to the
manufacturer’s instructions. cDNA of patients pre- and post-DBS on
stimulation and controls was also applied to Affymetrix human exon and
junction prototype microarrays (HJAY). (B) The junction array datasets
were processed in AltAnalyze using a previously described regression
approach (Sugnet et al., 2006) on junction pairs, followed by functional
enrichment analysis. Protein domains and enriched motifs and miRNA
binding sites were also identified. (C) Reads obtained by high throughput
sequencing were trimmed from adapter and end terminal bases and
were aligned to miRBase and the human filter reference sequences
database. The counts were standardized for common tag-wise dispersion
and tested for differential expression using both dispersion estimation
and Bayesian learning methods. (D) Predictions of miRNA: target
interactions with the spliced transcripts were conducted by using the
miRWalk algorithm which combines 8 established databases with
predictions beyond the 3′ untranslated region (3′-UTR).
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expressed genes. This involved B statistic ranking (logarithm
of the posterior odds that a gene is differentially expressed
(Lonnstedt, 2002) through the EdgeR package (Robinson et al.,
2010). Thus, the statistical approach applied here took into
account both technical and biological variability of the digital
count data.
Taking a B-statistic threshold of one, 16 out of the identi-
fied 332 miRNAs and one of the tRNA fragments previously
named hsa-mir-1280 (Schopman et al., 2010), were detected as
differentially expressed between PD patients and healthy control
volunteers (Figure 2A, full list under Table S6). Of the detected
miRNAs, 12 were predicted to bind AS regions detected as
changed in the junction arrays. Overall, 6 miRNAs were down
regulated and 10 up regulated in PD patients (Figure 2B), some
of which already shown as relevant to PD or other neurode-
generative diseases. For example, hsa-miR-16-1 and hsa-miR-16-
2, two precursors that yield the same mature hsa-miR-16 that
was recently identified as changed in PD blood cells (Margis
and Rieder, 2011), were decreased in PD leukocytes (log2 fold
change: −1.11, p-value: 0.026, expression under Figure 2B).
Inversely, the neuro-inflammatory regulator hsa-miR-20a that
is down-regulated in human aging (Hackl et al., 2010) and
is affected in Alzheimer’s disease (Delay et al., 2011) was up
regulated in patients (log fold change: 1.5, p-value: 0.002).
Elevated hsa-miR-20a-mediated suppression of the transcription
factor E2F1 can also impair transcription (Brock et al., 2009),
whereas potentiated targeting by mir-20a of the BMPR2 protein,
a pathogenic hallmark of pulmonary hypertension may com-
pete with BMPR2 regulation by the miR-17/92 cluster (Huang
et al., 2012) which was also identified as changed in our PD
patients data (log fold change: −1.16, p-value: 13.28). Among the
changed miRNAs was also the miR-17/92 cluster, which is regu-
lated by the pro-inflammatory cytokine interleukin (Il)-6 (Brock
et al., 2009). Intriguing, miR-320, which was modified in PD
patients as compared with matched healthy control volunteers
is included in a miRNA signature of prion-induced neurode-
generation (Saba et al., 2008), perhaps reflecting a feedback
response aimed to avoid disease symptoms that was potenti-
ated by DBS. Inversely, the tumorigenic miR-18b was elevated
in PD (Guo et al., 2008). Additionally, the recently identi-
fied primate-specific hsa-miR-1274b (log fold change: 1.07, p-
value: −11.79) which closely resembles a known tRNA was
also up regulated, predicting global aberrations in miRNA
metabolism. The PD-increased hsa-miR-21 (log fold change:
1.3, p-value: 0.02) also participates in a miRNA-based gene
dys-regulation pathway in Huntington’s disease (Johnson et al.,
2008), and potentiated suppression by hsa-miR-21 and hsa-
miR-150 of PTEN and Huntingtin would intercept T- and B-
cells proliferation (Krichevsky and Gabriely, 2008; Lundstrom,
2011). Also, the reduced hsa-miR-378 (log fold change: 2.25, p-
value: 0.000109) predicts impaired control over mitochondrial
metabolism (Carrer et al., 2012) and negatively regulated NK cell
cytotoxicity (Wang et al., 2012). Predicted decrease in another
target, the Alzheimer’s disease APP gene encoding for the amy-
loid precursor protein (Hébert et al., 2009) may indicate that at
least some of these miRNA changes reflect a protective feedback
response.
DBS INDUCES STIMULUS-DEPENDENT REVERSAL OF PD LEUKOCYTE
miRNA CHANGES
Patient leukocyte miRNAs were re-examined post DBS, upon
symptoms stabilization. Similar analysis identified differential
expression of 11 miRNAs, 8 down and 3 up-regulated as com-
pared to the pre-DBS state (p < 0.05, B statistics, Table S7 and
Figure 2C) and the two tRNA fragments which were previ-
ously annotated as two new miRNAs (Table S7) (Schopman
et al., 2010). Strikingly, 5 of the DBS-modified miRNAs were
among those that were changed in PD compared to healthy
volunteers but exhibited inverse direction of change post-
DBS as compared with the PD-induced change (Figures 2C,D).
For example, hsa-mir-20a and hsa-miR-378 increased in PD
patients and decreased post-DBS, whereas the inflammatory-
regulating hsa-miR-424 (Spinelli et al., 2013) showed no
change in PD but it’s passenger 3′ form (hsa-miR-18b-3p,
previously called star form) exhibited down-regulation follow-
ing DBS.
The DBS neurosurgery leads to greatly reduced medication
dosage (which was also the case in our cohort), raising the
possibility that the post-DBS changes were due to this reduced
dose and/or to the surgical procedure itself. To challenge these
questions, we also examined the small RNA transcriptome fol-
lowing 1-h stimulation cessation in the same group of patients.
Disconnecting the electrical stimulation rapidly re-induces the
motor disease symptoms that were apparent prior to the DBS
treatment (such as resting tremor). Rapid and dynamic changes in
miRNA expression were previously observed in several instances
[e.g., (Perry et al., 2008; Pang et al., 2009)], but were never tested
in live patients.
To isolate the effect of the electrical stimulation on the expres-
sion patterns of miRNAs in the blood we further analysed
the small RNA transcriptome of patients’ blood leukocytes fol-
lowing a 1 h of electrical stimulation cessation. Disconnecting
the electrical stimulus notably induced in this short time
lapse expression change in 11 miRNAs (six decreased and five
increased) Figures 2E,F and Table S8). This indicated that the
post-DBS miRNA changes were neither due to the lower med-
ication dose nor to the surgical procedure, but rather reflected
the retrieved motor symptoms under stimulus cessation. The
modified leukocyte miRNAs also differed in their copy num-
bers (for example, hsa-miR-20a expressed higher as compared
with hsa-miR-320, Figure 2G). One of the putative identified
as changed miRNA (hsa-miR-1280) is a fragment of a tRNA
(Griffiths-Jones et al., 2008). Disconnecting the electrical stim-
ulus further reversed the DBS-mediated change in hsa-mir-143
(Figure 2F). Correspondingly, the post-DBS miRNA profile dif-
fered from that of healthy volunteers by only nine miRNAs
(Figure S3) whereas 1 h OFF stimulation induced 4 miRNA
count changes as compared with the healthy state including hsa-
mir-320a and hsa-mir-320c (Figure S3). Taken together, these
findings imply that miRNA profiles in both post-DBS and the
OFF stimulus conditions differ from the pre-surgery disease
state. The oncogenic hsa-mir-16 (Diniz et al., 2012), which was
also observed in other PD blood cohort through RT-PCR as
changed (Margis and Rieder, 2011) and the tumorigenic miR-18b
(Guo et al., 2009).
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FIGURE 2 | Changed miRNA profiles in PD patients pre-and post-DBS
and under stimulation cessation. (A,C,E). Log concentrations (X -axis) and
log 2 fold change (FC) (Y -axis) of miRNAs detected as differentially expressed
in (A) PD patient leukocytes pre- DBS as compared with healthy volunteers,
(C) post-DBS on stimulation as compared to pre-DBS and (E) following 1h off
electrical stimulation. Red color denotes miRNAs that were detected as
exhibiting a statistically significant change in each condition. The yellow
(Continued)
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FIGURE 2 | Continued
dots represent all miRNAs that exhibited close to zero expression in one
or both conditions (thus they cannot be plotted on a log scale). These
condition-unique points in the plot are artificially represented by spreading
them vertically as a “smear” on the left. (B,D,F) The fold change and
p-value of miRNAs exhibiting down- or up-regulation in patients’ pre-DBS
compared to (B) healthy volunteers, (D) post-DBS on stimulation as
compared to pre-DBS and (E) post-DBS off stimulation compared to
on-stimulation (F). The length of the bar denotes the statistical
significance and the direction of change is denoted by positive or
negative direction of the bar. Y -axis: -ln (p-value)*log fold change. Marked
miRNA names: 5 (∼30%) of the miRNAs that were detected as changed
in PD patients were also detected as changed post-DBS and exhibited
reverse direction of change compared to the disease state. (G) The
non-normalized sequence read counts for selected changed miRNAs in
the four tested states.
SPLICE JUNCTION MICROARRAY ANALYSIS IDENTIFIES PD-RELATED
SPLICING CHANGES, INCLUDING IN miRNA BINDING SITES
The observedmiRNA leukocyte changes predicted corresponding
changes in the levels of target transcripts of modified miRNAs.
Given that the great majority of human genes are subject to splic-
ing regulation, based on our exon microarray-based detection
of exon microarrays-based detection of differential expression
changes in PD leukocytes (Soreq et al., 2012c), we hypothesized
that differential splicing regulation also exist in the patient’s blood
leukocytes. Furthermore, alternative isoforms that occur through
alternative polyadenylation can also result in the removal or addi-
tion of microRNA binding sites in the 3′ UTR. Supporting this
notion, the full splicing picture is far more complex than the
resolution level of the exon arrays technology, since each splic-
ing event may simultaneously cover one or more than one exon.
To accurately identify the complex scope of inclusion and exclu-
sion events in particular transcripts, we applied here human splice
junction arrays (HJAY) (Sugnet et al., 2006), which simultane-
ously interrogate all of the exons and all of the splice junctions
of each gene, enabling to construct a more robust combinatorial
splicing picture (Figure 3A).
To detect alternative exons regulated from these arrays, the
expression of pairs of opposing (reciprocal) exon-junctions were
compared using a previously described linear regression approach
(Sugnet et al., 2006) in the program AltAnalyze (Salomonis
et al., 2009) for ∼25,000 detected transcripts. This analysis
revealed 478 disease-associated inclusion and exclusion events
that occurred in 332 distinct genes, along with exons contain-
ing predicted miRNA binding sites (Table S9). These predictions
correctly classified the patients from control groups by both
the inclusion changed junction probe-sets (Figure 3B) and the
exclusion ones (Figure 3C). Of these changes, 142 events were
predicted to be functionally relevant (i.e., modifying a protein
domain or binding site effects). 31 of those predicted change in
a miRNA binding site. Statistical significance enrichment anal-
ysis identified nine miRNAs as frequently targeted at detected
spliced transcripts: hsa-miR-769-3p (predicted to target four
transcripts), hsa-miR-378 (with six targets) as well as hsa-mir-
320, hsa-miR-92b-5p, hsa-miR-16, hsa-miR-150, hsa-miR-671,
hsa-miR-20a, and hsa-miR-18b (The full list and adjusted p-
values are given under Table S10). The enriched differentially
expressed miRNAs were predicted to target 14 spliced tran-
scripts, including the reactive oxygen species modulator ROMO1,
the RNA-binding motif RBM6 transcript involved in splicing
(Heath et al., 2010) and the splicing factor hnRNPA2B1. Three
newly annotated miRNAs were only identified in the small
RNA sequencing data. PD-mediated inclusion of exon 12 in
the exon 12 of the hnRNP gene hnRNPA2B1 was detected by
a mutual change in three junction probe-set pairs sharing the
same second probe-set (Table S9). Notably, hnRNPA2B1 has a
role in regulating the biogenesis of miRNAs and in up-regulating
hsa-miR-18a (Guil and Caceres, 2007) and down-regulating
hsa-let-7 (Eddington et al., 2007). Recently, a link was found
between mutation in this hnRNP and the neurological disease
Amyotrophic lateral sclerosis (ALS) (Kim et al., 2013). Also, we
recently found that hnRNPA2B1 is essential for neuronal well-
being in Alzheimer’s disease (Berson et al., 2012), compatible
with the stress-associated changes in AS (Meshorer et al., 2002).
The domain that we found here as included in PD patients
extends the c-terminus of the hnRNPA2B1 protein that is neces-
sary for nuclear localization and is sufficient for sending cytosolic
proteins to the nucleus in a phosphorylation-regulated man-
ner (Allemand et al., 2005). Furthermore, hnRNPA2B1 mediates
mRNA shuttling to distal processes in both neuronal cells and
oligodendrocytes (Han et al., 2010), and blockade of its func-
tion by splice-isoform-specific antibodies impaired the assembly
of RNA granules. Notably, the extended domain spans puta-
tive binding sites for several PD-modified miRNAs (including
hsa-miR-320a, hsa-miR-320b, and hsa-miR-320c), together indi-
cating that the observed inclusion events may entail functional
relevance.
Post-hoc functional GO analysis through the GO-Elite module
of AltAnalyze of the regression detected genes revealed enrich-
ment in transcripts of cellular components of the ubiquitin lig-
ase complex (GO:0000151, p = 0.0165) and biological processes
of mitochondrion organization (GO:0007005, p = 0.0185) and
regulation of translation (GO:0006417, p = 0.015) (Table S11).
The FOXP1 transcript showed disease-mediated exclusion in
PD patients, which was further annotated as replacing the N-
terminus in the 679 amino acid long FOXP1 protein by an
alternative N-terminus that yields a shorter protein product of
573 residues.
Independent exon-level splicing-index (Gardina et al., 2006)
analysis of the exon probe sets present on the junction microar-
rays detected 202 PD-inducible AS events pre-DBS (Table S12).
The detected exon interrogating probe-sets successfully classi-
fied patients from controls by expression level (Figure S4). The
interrogated spliced genes that included the changed probe-
sets exhibited enrichment in AS and apoptotic nuclear changes
(Table S13). Of the exon level detected disease regulated genes,
34 were among these detected by the linear regression anal-
ysis of reciprocal junction pairs. However, only four of the
detected alternative exons were annotated as overlapping with
alternative polyadenylation sites, in the 3′ UTR (Table S12). Of
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FIGURE 3 | Alternatively spliced exon-junction pairs classify PD and
post-DBS samples correctly. (A) A schematic illustration of the
interrogated gene regions and possible combinations of inclusion and
exclusion of junction and exon probe-sets. Dashed lines: possible
inter-exonic Probe Selection Region (PSR) combinations with exclusion of
junction probe-sets. A splice change is defined where bi-directional
changes occur in the inclusion and the exclusion probe-sets (or
alternatively, in a PSR and exclusion probe-sets) concurrently between
two tested states. (B) The global expression of inclusion junction array
probe sets that were detected as changed classified patients from
healthy volunteers successfully. (C) Classification by the exclusion junction
probe-sets. (D) Classification following DBS classified post-DBS from
pre-treatment state by inclusion detected probe-sets. (E) Internal exon
classification of the post-DBS from pre-DBS states by PSRs. (F)
Classification by the DBS-modified exclusion junction probe-sets. Distance
method for all the clusterograms: city block.
the 202 identified events, 127 had functional predictions such
as alternative terminals or non-sense-mediated decay regions
(Table S12). Of these, 36 (∼30%) were functionally predicted as
miRNA binding sites (Table S14). Enrichment analysis detected
6 of the DBS-modified miRNAs as modified (having adjusted p-
value < 0.05): hsa-miR-320 (a, b, and c) as predicted to bind
4 spliced transcripts including hnRNPA2B1, hsa-miR-378 (pre-
dicted to bind 6 spliced transcripts), hsa-miR-92b (predicted to
bind 4 spliced transcripts), hsa-mir-150, hsa-miR-20a, and hsa-
miR-18b (where hsa-miR-18b-3′ changed). Overall, the disease-
modified miRNAs were predicted to target overall 11 spliced
target transcripts, including ROMO1 and COL6A2 that were
each predicted as targets of four different modified miRNAs
(Table S14).
SPLICE JUNCTION MICROARRAYS IDENTIFY SPLICE ISOFORM
CHANGES FOLLOWING DBS INCLUDING IN miRNA PREDICTED
BINDING SITES
To identify splicing changes induced by DBS, we compared the
splice junctions of patients post-DBS to these of pre-DBS state.
Linear regression analysis was conducted through AltAnalyze
software package (Salomonis et al., 2010) which was adopted for
the human junction arrays. The analysis demonstrated a more
limited AS induction of 155 inclusion and exclusion events in 117
genes (Table S15). Of these, 140 entailed functional predictions,
109 changing protein domain(s) and 31 modifying miRNA bind-
ing sites (Table S15). For ∼1/3rd of the detected splicing events,
an additional internal exon probe set reproduced the junction-
level results (45 out of 155), indicating higher confidence exon
expression changes. Each of these measurement types (inclusion
junction, exclusion junction, or inclusion exon) properly segre-
gated the post-DBS samples from pre-DBS ones: the inclusion
junction probe-sets (Figure 3D), the exon probe-sets (Figure 3E)
and most distinctly, the exclusion probe-sets (Figure 3F), which
showed an inverse pattern of change to that observed for PD,
completely segregating the post-DBS samples from pre-DBS ones.
The linear regression detected genes were enriched in the molec-
ular processes of RNA import into nucleus and MAPK phos-
phatase export from nucleus as well as in ubiquitin homeostasis
(Table S16).
DBS induced potentiated reduction in the junction pair mea-
suring exclusion of the PD-included region of hnRNPA2B1, how-
ever, with two additionally decreased internal exons. Thus, PD
hnRNPA2B1 transcripts showed lower expression of the inter-
nal exon probe-set as compared with control volunteers, and
post-DBS state caused a yet lower level of this internal region;
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and the opposite trend was found in the corresponding junction
probes, reinforcing the conclusion that an exclusion event had
occurred.
Exon level splicing-index analysis of PD patients post-
compared to pre-DBS detected 131 AS events in 117 genes
(Table S17), in 20 of them junctions were also detected as changed
through the linear regression analysis of patients post- compared
to pre-DBS. The detected exon-interrogating probe-sets suc-
cessfully classified post- from pre-DBS samples (Figure S5).
Intriguingly, 89 of the detected exons had functional transcript
structure predictions. Two of these were annotated in Poly(A)
sites (Table S17), and one of these predictions occured in the
Toll-like receptor (TLR)3, a pro-inflammatory cytokine mediator
(Butt et al., 2012). The NCBI web-based functional annota-
tion tool DAVID (Database for Annotation, Visualization and
Integrated Discovery) was used to investigate functional associ-
ations of splicing changes seen in the patients’ blood leukocytes
following DBS. Functional analysis using the DAVID EASE tool
(Hosack et al., 2003) revealed that the DBS modified genes were
functionally enriched in response to metal ion, AS, apoptosis,
immune response and mitochondrion organization (Table S18).
Enrichment analysis for miRNA binding sited in the detected
genes detected 3 of the DBS-modified miRNAs: hsa-miR-20, hsa-
mir-18, and hsa-miR-143 as highly predicted to bind AS targets
detected by the exon level analysis (Table S19).
PD BRAIN REGION TRANSCRIPTOMES REVEAL DISEASE-ASSOCIATED
EXPRESSION CHANGES IN THE ALTERNATIVELY SPLICED LEUKOCYTE
TRANSCRIPTS
Expression profiling of the alternatively spliced transcripts iden-
tified by junction microarray analyses of PD leukocytes was
independently examined in a large microarray dataset of PD
Patient’s brain samples (Moran et al., 2006). The external dataset
was composed of 3′ microarray data obtained from post mortem
brain samples from PD patients and matched healthy con-
trol volunteers and included three brain regions: the lateral
and medial substantia nigra and the superior frontal gyrus.
The expression of 707 probe sets interrogating genes that were
found as alternatively spliced (Table S20) successfully classi-
fied patients from control samples in this independent data-set
(Figure 4), reflecting brain region specificity of the tested tran-
scriptomes. The brain regions were further segregated by the
blink classifier which separated the frontal gyrus from the sub-
stantia nigra (Figure 4). In the medial substantia nigra, all the
patients were correctly classified apart from the control volun-
teers. Two lateral substantia nigra control samples were mis-
classified with the patients, and two of eight patients were mis-
classified with the control volunteers based on the expression in
the superior frontal gyrus. Thus, the vast majority of the sam-
ples were correctly classified as patients or control volunteers
and overall over 91% accuracy of classification was obtained
(Figure 4).
CELLULAR COMPOSITION OF PARKINSON PATIENTS LEUKOCYTES
To identify the most likely cell types and tissues represented
in the samples analysed by small RNA deep sequencing and
microarrays, we have conducted a cell lineage analysis of the exon
FIGURE 4 | Brain expression levels of spliced transcripts classify PD
patients from control volunteers in a brain-region dependent
manner. Shown is a hierarchical classification in the noted brain regions
of those same transcripts found to be alternatively spliced in PD
leukocytes. Note that the hierarchical classifier successfully classified
patients from healthy control volunteers based on expression levels
obtained by 3′ microarrays interrogating three post mortem brain regions:
superior frontal gyrus (SFG), medial substantia nigra (MSN) and lateral
substantia nigra (LSN). Each row corresponds to one probe set
interrogating a gene that was detected as alternatively spliced in
leukocytes from patients and each column represents one sample of
brain transcriptome from either patient (red) or healthy volunteer (green)
from the independent cohort (Moran et al., 2006). The frontal brain
region was correctly segregated from both substantia nigra regions by
the expression data, and overall 43 of the 47 samples (∼91.5%) were
correctly classified as healthy or Parkinsonian ones.
microarray data of seven patients examined in three states each
and the six control volunteers using a newly developed module
of AltAnalyze software package called LineageProfiler program.
A large human and mouse compendium of publically available
microarray datasets (from the GEO public repository) were used
to identify gene sets for each cell type or tissue with the high-
est correlations to an idealized binary expression profile. The
analysed samples included these tested also by junction microar-
rays and small RNA deep sequencing. The results were visual-
ized as association scores at the level of hierarchically clustered
cell types and curated lineage networks (Figure 5). The created
database reflects the most specifically-expressed exons present in
the samples, relative to all lineages types examined. We identified
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substantial immune cell activity in the patient’s blood leuko-
cytes both pre and post- treatment. Furthermore, most healthy
individual samples were classified with post-treated patients and
pre-treated patients with the off stimulation state based on the
expression data of the marker genes.
PD-SPLICED TRANSCRIPTS SHOW MULTIPLE GENE-WIDE BINDING
SITES FOR PD-MODIFIED miRNAs
Recent evidence indicates miRNA targeting beyond the 3′-UTR
(Orom et al., 2008; Lee et al., 2009). Therefore, we extended
the search for putatively changed miRNA-AS pairs to both the
coding region and the 5′-UTR using miRWalk (Dweep et al.,
2011). The miRWalk database, which predicts miRNA binding
sites on the complete sequence of each gene, includes thousands
of predicted targets for each of the PD-differentially expressed
miRNAs. Using this information, we constructed a network of
potential links between the 13 PD-differentially expressed miR-
NAs and the 217 target transcripts that showed AS changes in
PD (Figure 6A), which exhibited more inclusion than exclusion
events (Figure 6B). A total of 560 putative connections emerged
(an average of 2.6 miRNA binding sites/target gene), with 43% of
those on the 3′ UTR, 38% in the coding sequence and the remain-
ing 19% in the 5′ UTR of the AS target genes (Figure 6C). This
could not be explained by the relative length of the different gene
regions of the identified links, since the average fraction (out of
the total length for all genes) is 24% for the 3′ UTR, 69% for the
coding sequence and only 7% for the 5′ UTR (Mazumder et al.,
2003; Sakharkar et al., 2004b). The network showed a remarkable
asymmetry containing the highest number of spliced junctions
(68) in predicted targets for miR-16 and the lowest (1) for hsa-
miR-18b-3p (previously called hsa-miR-18b∗). Supporting the
notion of disease relevance, this network included several known
PD-related genes such as the transcriptional regulator FOXP1
(Kim et al., 2007), that promotes midbrain dopaminergic iden-
tity in stem cells (Konstantoulas et al., 2010), which was identified
as alternatively spliced in this study and was predicted as tar-
geted by the PD dys-regulated hsa-miR-320 cluster. We conclude
that at least some of the PD-modified miRNAs may poten-
tially interact with part of the AS-modified transcripts in PD
leukocytes.
DBS-SPLICED TRANSCRIPTS SHOW MULTIPLE GENE-WIDE BINDING
SITES FOR DBS-MODIFIED miRNAs
An independent network was constructed for the DBS-modified
miRNAs and their DBS-spliced predicted targets (Figure 7A).
Similar to the PD network, it included more AS predicted targets
exhibiting inclusion (rather than exclusion) events (Figure 7B),
with binding prediction again showing a decreasing order from
the 3′ UTR (45%), coding sequence (35%) to the 5′ UTR (20%)
(Figure 7C).The pair-sample DBS network was predictably thin-
ner than the PD one as it avoided inter-individual variability
and was based on smaller numbers of DBS-modified miR-
NAs and AS target transcripts. Nevertheless, this network as
well showed asymmetry, with many more predicted AS tar-
gets for hsa-miR-424. The two networks shared four miR-
NAs that their predicted targets were modified both in PD
and after DBS as compared with healthy volunteers. Of these,
hsa-miR-378, and hsa-miR-20a were predicted to bind the same
seven AS target genes, affecting the actin-associated protein
VASP involved in axon guidance (Mohamed et al., 2012), the
hemoglobin subunit gamma-2 HBG2 gene, the retinoic acid
receptor responder RARRES3, the androgen-regulated solute car-
rier SLC14A1 (Vaarala et al., 2012), TMEM69, a dividing leuko-
cytes biomarker (Solmi et al., 2006), the mitochondrial tRNA
dimethyl-allyltransferase trit1 and the bZIP nuclear transcription
factor. Other identified targets were the cAMP-responsive modu-
lator CREM, which has known spliced isoform variants (Sanborn
et al., 1997) and regulates target genes in different tissues (Fimia
et al., 2000) and which associates with panic disorder (Domschke
et al., 2003), depression and bipolar disorder (Crisafulli et al.,
2012) and the schizophrenia-mutated GABA receptor modula-
tor DBI which encodes a diazepam binding inhibitor (Niu et al.,
2004).
We found three target genes (HBG2, RARRES3, and VASP)
common to both networks to be regulated by the same miRNAs
predicted to target the same junction probe-set pairs (Figure 7A),
and in opposite directions from healthy controls to PD patients
as compared with pre- to post-DBS. This is a remarkable overlap
given that the DBS network was much narrower than the PD one
and that the patient’s pre-DBS changes were unpaired with the
healthy volunteers.
The observed changes in miRNA-AS interactions in both
PD and following DBS further raised the question if the pre-
dicted binding sites coincided with the modified splice junctions.
Sequence comparisons of the miRNA seed regions with the junc-
tion probe sets that exhibited splicing changes identified such
PD-and DBS-modified links in 34 (Table S21) and 33 events
(Table S22) from 13 and 5 spliced transcripts, respectively. Given
that this is only a small fraction of the modified transcripts in
each case, this finding demonstrates that the great majority of the
observed interactions did not involve active splicing events, while
suggesting that direct miRNA-mediated splicing regulation is a
viable, albeit exceptional case where the predicted binding site was
located exactly in an alternatively spliced junction (Tables S21
and S22). Exceptional PD-related examples of seemingly active
miRNA-spliced transcripts predicted interactions includeUSP13,
which promotes smooth (SMO) signaling by preventing its ubiq-
uitination (Xia et al., 2012), RGS3 which contributes to neural
progenitor/stem cell regulation (Qiu et al., 2010) and MGAT1,
involved in multiple sclerosis (Grigorian et al., 2012). The DBS-
induced events occurred in the NPC2 gene, which shares choles-
terol interactions with alpha-synuclein (SNCA) (Liu et al., 2010),
as well as inHLX,C11orf5,CREM, and the poly-A binding protein
coding transcript PABPC1L.
DISCUSSION
Our study provides the first report of complete small RNA tran-
scriptome sequencing of live human PD patients’ blood leuko-
cytes. Using a whole transcriptome high throughput sequencing
technique in conjunction with analyses of both exon and junction
microarrays interrogating RNA from the same cells of patients
prior to brain stimulation treatment and post-treatment while
being on and off electrical stimulation as well as of healthy
volunteers, we characterized differential expression in miRNAs
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FIGURE 5 | Tissue and cell type origins of leukocyte-expressed
AS-modified long transcripts. Putative cell and tissue specific markers
subjected to alternative splicing in the leukocyte RNA samples from tested
patients and controls were hierarchically classified by exon array gene level
expression (columns) and markers (rows). The color code scale presents
lineage correlation Z -scores.
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predicted to bind target transcripts that underwent splicingmodi-
fications.We have successfully classifiedmicroarray brain samples
of an independent patients cohort based on the expression lev-
els of genes that were found as alternatively spliced in blood
leukocytes, at high accuracy of over 91%. Moreover, the dual
comparative analysis of patients pre- and post- treatment as
well as compared to healthy volunteers yielded insights into
both disease and treatment mechanisms. Practically all of the
human genes are simultaneously subject to post-transcriptional
regulation by either AS or miRNAs thus both miRNAs and
spliced isoforns represent promising new candidates for PD
research.
For the small RNA sequencing, we used SOLiD genome
analyser, obtaining ∼106 reads per sample, which is consid-
ered a sufficient coverage for small RNA profiling, with above
50% average mapping to the miRBase database, detecting about
half of miRBase miRNAs in the samples in up to millions of
copies for few of them. For comparison, alignment to a different
FIGURE 6 | A complex disease network of miRNA-spliced targets
expanding beyond the 3′-UTR. (A) Circular tree layout of the network of
connections between the miRNAs detected as differentially expressed in PD
patients to their predicted target genes that exhibited AS change in splice
junction microarrays. External circle: red node color indicates exclusion event
in the predicted target splice junction and green—exclusion. Larger node size
indicates higher number of connections. The color of edges represents the
gene region in which the binding is predicted to occur (5′ , 3′ -UTR or coding
sequence, CDS). Middle circle: the predicted target genes. Gray circle color
highlights miRNAs targeting the PD-related gene FOXP1, previously linked to
miRNA regulation. Curved lines in the inner circle denote two different
regions predicted to be bound (e.g., 3′ UTR and coding sequence). (B) PD
patients exhibited more inclusion events (green) as compared with exclusion
(red). (C) The types of events predicted to be regulated by the changed
miRNAs: 3′ un-translated region (UTR) (dark blue), 5′ UTR (orange) or coding
sequence (CDS, light blue).
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FIGURE 7 | The treatment induced network partially overlaps with the
disease network. (A) A circular tree layout network of connections
between miRNAs that exhibited differential expression following DBS
neurosurgery as compared with the pre-DBS (non-stimulated) state, and
their predicted target genes that exhibited alternative splicing changes in
PD patients following the DBS treatment. External circle: red node color
indicates exclusion event in the predicted target splice junction and
green—exclusion. Larger node size indicates higher number of
connections. The color of edges represents the gene region in which the
binding is predicted to occur (5′ , 3′-UTR or coding sequence, CDS).
Middle circle: the predicted target genes. Curved lines in the inner circle
denote two different regions predicted to be bound (e.g., 3′ UTR and
coding sequence). Black miRNAs and dark blue target genes: overlap with
the patients compared to healthy network presented in Figure 6. (B) The
number of exon exclusion (red) and exon inclusion (green) events detected
in the predicted target genes that were detected by linear regression
analysis of reciprocal junction pairs interrogated by junction microarrays
(Y -axis: number of detected events). (C) The types of events predicted to
be regulated by DBS modified miRNAs: 3′ un-translated region (UTR) (dark
blue), 5′ UTR (orange) or coding sequence (CDS, light blue).
reference sequence database of other (non-miRNA) non-coding
human RNAs yielded only an average of ∼9% alignment over
all the sequenced libraries, supporting the notion that the miR-
NAs are composing the largest population of non-coding RNAs
found in the studied human leukocyte samples. Concurrently,
we employed splice junction and exon microarrays to generate
parallel transcriptome datasets from the same cells in order to
identify AS changes in the modified miRNAs predicted targets,
as well as the cellular composition changes in patients and post-
treatment. Testing the same patients before and after surgery
further overcame individual variability. Further studies which will
expand the size of the tested cohort will enable validation of our
findings in larger and independent patient and healthy volunteer
cohorts.
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We identified significant changes in 16 miRNAs in PD and in
11 post-DBS treatment, 5 of which were among these changed in
the disease, but inversely, reinforcing the disease and treatment
relevance of these changes. The post-DBS change was further
dependent on the stimulus itself, as 1-h off-stimulus completely
changed the modified miRNA profiles as compared with the stim-
ulated state. We also identified expression changes in two newly
proposedmiRNAs that were recently reported as tRNA fragments,
possibly originated from the antisense copy of an endogenous
retroviral element (Kawaji et al., 2008; De Hoon et al., 2010).
The observed miRNA changes post DBS were compatible with
miRNA expression being subject to rapid changes undermodified
environmental conditions (Brzuzan et al., 2012) and immunolog-
ical challenges (Perry et al., 2008) and indicating possible rele-
vance to the DBS-suppressed symptoms. To our knowledge, our
study is the first to construct differential disease- and treatment-
related networks in human cells from neurodegenerative disease
patients.
Analysis of gene isoform differential expression, AS and mod-
ifications of miRNA binding sites revealed significant differences
in splice isoform profiles between PD patients and healthy con-
trol volunteers blood leukocytes, as well as in post- compared
to pre-DBS states, following the brain stimulation treatment. We
identified enrichment of immune cellular composition by lin-
eage cell profiling analysis of the exon microarrays, both pre-
and post-DBS. Through database and network analyses we iden-
tified disease and treatment networks of miRNAs and spliced
targets. Combining the data from differential expression of miR-
NAs with the changes in expression of their potential targets in
a systematic way is a powerful tool to identify disease related
miRNA-target gene networks. In this study we combined miRNA
expression profile in PD patients pre- and post-treatment with
data of splice junction microarrays from the same samples pre-
senting a systems biology approach for studying blood leukocyte
RNA expression patterns in neurological and neurodegenerative
diseases.
Intriguingly, there were more predicted binding sites in the 3′
UTR as compared with the other regions, compatible with other’s
observations for more efficient regulation of the target genes
through 3′-UTR binding. Whereas binding to the 3′ UTR induces
stronger degradation of the target, auxiliary binding to the cod-
ing sequence may possibly increase this effect. Recent reports that
target regulation through miRNAs may function also in coding
regions, not only the 3′ UTR (Dolken et al., 2010; Hafner et al.,
2010) are compatible with our predictions. Correspondingly,
computational analyses of data produced from RNA-binding
protein PAR-CLIP [Photoactivatable-Ribonucleoside-Enhanced
Crosslinking and Immunoprecipitation, (Ule et al., 2003)] exper-
iments showed that nearly 50% of the miRNA binding sites
were located in the coding regions of the targets, compatible
with the capacity of miRNAs to each regulate thousands of tar-
get mRNAs (Lewis et al., 2005; Friedman et al., 2009). Yet,
the molecular mechanisms underlying the selection of inter-
action between distinct “seed” domains and single transcripts
was not yet interrogated in a global manner in human diseases;
therefore, the identification of more than a single miRNA-target
putative interaction site opens yet more questions, for future
studies.
The state specific enrichment for GO processes suggests
disease- and treatment-specific functional involvement. The
disease induced processes included ubiquitin ligase complex,
mitochondrion organization and regulation of translation, com-
patible with our recent observations in brains of PD model
mice (Soreq et al., 2012a). The DBS induced functional changes
included MAPK phosphatase export from nucleus as well as in
ubiquitin homeostasis, suggesting treatment influence on disease
leukocyte pathways.
While the majority of small RNAs are found within the cells,
a growing number of miRNAs are observed outside cells, includ-
ing various body fluids and blood (Caby et al., 2005; Garcia et al.,
2008). For example, small RNA deep sequencing identified miR-
NAs in exosomes, membrane-bound nanoparticles which are a
newly described pathway of intercellular communications (Zhang
and Grizzle, 2011), with a distinct signature during prion infec-
tion (Bellingham et al., 2012). Circulating miRNAs were recently
suggested as new biomarkers in diagnosis, prognosis, and treat-
ment of cancer (Allegra et al., 2012). Moreover, extracellular
RNAs have immune-modulating properties (Altincicek et al.,
2008) and can escape the blood-brain barrier to reach distal loca-
tions (Graner et al., 2009) or to tumors. This suggests a future
venue to pursue.
Epigenetic chromatin changes were recently found in blood
leukocytes of schizophrenia patients (Melas et al., 2012), where
association was found between DNA methylation and antipsy-
chotic drug treatment. As PD also entails hereditary component
in about 10% of the cases, it will be highly interesting to pur-
sue in the future for genome-wide DNA methylation changes
in PD patients prior to, and following DBS, which may reveal
dysregulated epigenome in PD and may further discover DNA
methylation disease biomarkers in blood leukocytes.
Concurrent measurements of miRNAs and their mRNA tar-
gets were recently reported for two other human diseases:
Myelodysplastic Syndromes (Beck et al., 2011) and multiple scle-
rosis (Angerstein et al., 2012) but these studies did not address
splice isoform and AS changes of the targets. To our knowl-
edge, this is the first report where quantitative information about
miRNAs has been generated concurrently with particular splice
variants in a genome wide scale for blood leukocytes of human
patients prior to, and post brain stimulation treatment. Thus,
our study provides a useful data set supplementing previous
microarray datasets of transcripts, which lacked isoform-specific
resolution, and provides a comparative resource for miRNA study
in PD.
The PD network included the transcription factor FOXP1,
implicated in a miRNA-mediated feedback loop controlling the
survival of midbrain dopaminergic neurons (Kim et al., 2007),
and shown to co-act with PITX3 for maintaining neuronal fate
in the midbrain. Specifically, PITX3 promotes midbrain iden-
tity through regulation by this dopaminergic regulator (De Mena
et al., 2010; Konstantoulas et al., 2010). These findings suggest
relevance of the observed changes for both the PD phenotype
and treatment efficacy, and foresee the use of similar network
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approaches for the study of other neurological and neurodegen-
erative diseases.
The identified miRNA changes in PD patient’s blood leuko-
cytes here may provide an important biomarker profile, reflecting
remarkable dynamics and stimulus-dependent reversal of miRNA
expression. Our data set provide a source for miRNA expression
in blood leukocytes in healthy state and under neurodegenera-
tive disease. Our analyses and findings suggest disease-associated
dys-regulation and treatment-related reversal of the transcrip-
tional mediated checks and balances that, under healthy state
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Figure S1 | The percentage of annotated reads and of the miRBase aligned
reads. (A) Percent of annotated reads of the total number of RNA-Seq
reads in all the 12 RNA-Seq libraries. (B) Percent of miRBase detected
entries in the RNA-Seq libraries (C) Percent of sequence match between
the reads and the miRBase sequences (perfect, 1 mismatch, 2
mismatches and 3 mismatches) (D) Percent of reads match to the human
reference sequences database (which comprises of non protein-coding
RNAs other than miRNAs, such as SINEs and ALU sequences).
Figure S2 | Expression map of selected miRNAs and miRNA∗ (3′/5′ forms)
in blood leukocytes of Parkinson’s patients pre- and post- treatment and
of healthy control volunteers. Read counts of selected miRNAs that were
detected through RNA-Seq alignment of small RNAs detected in blood
leukocytes of PD patients pre- and post-DBS while being on and off
electrical stimulation and of matched healthy control (HC) volunteers to
the miRBase database. (A) Highly expressed miRNAs (B) Highest
expressed, and (C) Count levels of miRNA∗ (3′/5′) forms presenting low
expression (D) and high expression (E). Y axis: the number of reads. Dark
blue: the expression of miRNAs in HC volunteers, lighter blue: in PD
patients pre-DBS, light blue: post-DBS while being on electrical
stimulation (DBS) and lightest: in PD patients post-DBS following one hour
of a complete electrical stimulation cessation (DBS-off).
Figure S3 | DBS differentially expressed miRNAs. Presented are miRNAs
that were detected as changed in PD patients post-DBS as compared with
HC volunteers (left), the same patients while being off electrical
stimulation state as compared with healthy control volunteers (middle)
and in off electrical stimulation state as compared with the pre-surgical
state (right). Y axis: fold change multiplied by the ln (log base 10) of the
significance p-value which was obtained by a negative binomial
distribution test through a generalization of the Poisson model that
recaptures biological variance correctly (Robinson and Smyth, 2008).
Figure S4 | Classification of patients pre-DBS from healthy control
volunteers. The junction microarrays expression levels of blood
leukocyte RNA exons that were detected as changed in PD patients as
compared with HC volunteers correctly classified patient samples apart
from the healthy samples. The unsupervised hierarchical classification
was conducted on the expression signals of the exons detected by
splicing-index analysis which was conducted by a modified version of
AltAnalyze (Salomonis et al., 2009) that was adopted to the human
splice junction (HJAY) arrays and is based on the measurement
described for exon arrays under (Gardina et al., 2006). The classification
was conducted with Euclidean distance measure on both the exons and
the samples.
Figure S5 | Classification of patients post-DBS from pre-DBS state. The
junction microarrays expression levels of blood leukocyte RNA exons that
were detected as changed by splicing-index analysis in PD patients
pre-DBS as compared with post-DBS (DBS) state (while being on
electrical stimulation) correctly classified between the states. The
classification was conducted by a hierarchical classifier with Euclidean
distance measure on both the exons and the samples.
REFERENCES
Affymetrix Technical Notes. Guide to





Allegra, A., Alonci, A., Campo, S.,
Penna, G., Petrungaro, A., Gerace,
D., et al. (2012). Circulating
microRNAs: new biomarkers in
diagnosis, prognosis and treatment
of cancer (Review). Int. J. Oncol. 41,
1897–1912.
Allemand, E., Guil, S., Myers, M.,
Moscat, J., Caceres, J. F., and
Krainer, A. R. (2005). Regulation
of heterogenous nuclear ribonu-
cleoprotein A1 transport by
phosphorylation in cells stressed by
osmotic shock. Proc. Natl. Acad. Sci.
U.S.A. 102, 3605–3610.
Altincicek, B., Stotzel, S., Wygrecka,
M., Preissner, K. T., and Vilcinskas,
A. (2008). Host-derived extracel-
lular nucleic acids enhance innate
immune responses, induce coagu-
lation, and prolong survival upon
infection in insects. J. Immunol. 181,
2705–2712.
Angerstein, C., Hecker, M., Paap, B.
K., Koczan, D., Thamilarasan, M.,
Thiesen, H. J., et al. (2012).
Integration of MicroRNA
databases to study MicroRNAs
associated with multiple
sclerosis. Mol. Neurobiol. 45,
520–535.
Ashburner, M., Ball, C. A., Blake,
J. A., Botstein, D., Butler, H.,
Cherry, J. M., et al. (2000). Gene
ontology: tool for the unifi-
cation of biology. Nat. Genet.
25, 25.
Atz, M., Walsh, D., Cartagena, P., Li, J.,
Evans, S., Choudary, P., et al. (2007).
Methodological considerations for
gene expression profiling of human
Frontiers in Molecular Neuroscience www.frontiersin.org May 2013 | Volume 6 | Article 10 | 17
We thank the patient and healthy volunteers that partici-
pated in this study. This work was supported by the Israeli
Chief Scientist to Hagai Bergman and David S. Greenberg, the
Thyssen Foundation to Hermona Soreq. and to Hagai Bergman,
and the Rosetrees foundation and the European Network of
excellence on alternative splicing (EURASNET) to Hermona
Soreq. Lilach Soreq thanks HUJI sources for PhD fellowship
support.
Soreq et al. Parkinson leukocyte miRNA-splicing profiles
brain. J. Neurosci. Methods 163,
295–309.
Beck, D., Ayers, S., Wen, J., Brandl, M.
B., Pham, T. D., Webb, P., et al.
(2011). Integrative analysis of next
generation sequencing for small
non-coding RNAs and transcrip-
tional regulation in Myelodysplastic
Syndromes. BMC Med. Genomics
4:19. doi: 10.1186/1755-8794-4-19
Bellingham, S. A., Coleman, B. M.,
and Hill, A. F. (2012). Small RNA
deep sequencing reveals a distinct
miRNA signature released in exo-
somes from prion-infected neu-
ronal cells. Nucleic Acids Res. 40,
10937–10949.
Bergman, H., Wichmann, T., and
Delong, M. R. (1990). Reversal
of experimental parkinsonism by
lesions of the subthalamic nucleus.
Science 249, 1436–1438.
Bernal-Pacheco, O., Limotai, N.,
Go, C. L., and Fernandez, H. H.
(2012). Nonmotor manifestations
in Parkinson disease. Neurologist
18, 1–16.
Berson, A., Barbash, S., Shaltiel, G.,
Goll, Y., Hanin, G., Greenberg,
D. S., et al. (2012). Cholinergic-
associated loss of hnRNP-A/B in
Alzheimer’s disease impairs corti-
cal splicing and cognitive func-
tion in mice. EMBO Mol. Med. 4,
730–742.
Braak, H., and Del Tredici, K.
(2008). Invited article: nervous
system pathology in sporadic
Parkinson disease. Neurology 70,
1916–1925.
Brock, M., Trenkmann, M., Gay, R.
E., Michel, B. A., Gay, S., Fischler,
M., et al. (2009). Interleukin-
6 modulates the expression of
the bone morphogenic pro-
tein receptor type II through a
novel STAT3–microRNA cluster
17/92 pathway. Circ. Res. 104,
1184–1191.
Brzuzan, P., Wozny, M., Wolinska, L.,
and Piasecka, A. (2012). Expression
profiling in vivo demonstrates
rapid changes in liver microRNA
levels of whitefish (Coregonus
lavaretus) following microcystin-LR
exposure. Aquat. Toxicol. 122-123,
188–196.
Butt, A. Q., Ahmed, S., Maratha,




J. Biol. Chem. 287, 38665–38679.
Caby, M. P., Lankar, D., Vincendeau-
Scherrer, C., Raposo, G., and
Bonnerot, C. (2005). Exosomal-like
vesicles are present in human
blood plasma. Int. Immunol. 17,
879–887.
Carrer, M., Liu, N., Grueter, C. E.,
Williams, A. H., Frisard, M. I.,
Hulver, M. W., et al. (2012). Control
of mitochondrial metabolism
and systemic energy homeostasis
by microRNAs 378 and 378∗.
Proc. Natl. Acad. Sci. U.S.A. 109,
15330–15335.
Crisafulli, C., Shim, D. S., Andrisano,
C., Pae, C. U., Chiesa, A., Han,
C., et al. (2012). Case-control asso-
ciation study of 14 variants of
CREB1, CREBBP and CREM on
diagnosis and treatment outcome
in major depressive disorder and
bipolar disorder. Psychiatry Res. 198,
39–46.
De Hoon, M. J., Taft, R. J., Hashimoto,
T., Kanamori-Katayama, M.,
Kawaji, H., Kawano, M., et al.
(2010). Cross-mapping and the
identification of editing sites
in mature microRNAs in high-
throughput sequencing libraries.
Genome Res. 20, 257–264.
Delay, C., Calon, F., Mathews, P., and
Hebert, S. S. (2011). Alzheimer-
specific variants in the 3′UTR
of Amyloid precursor pro-
tein affect microRNA function.
Mol. Neurodegener. 6:70. doi:
10.1186/1750-1326-6-70
De Mena, L., Coto, E., Cardo, L. F.,
Diaz, M., Blazquez, M., Ribacoba,
R., et al. (2010). Analysis of the
Micro-RNA-133 and PITX3 genes
in Parkinson’s disease. Am. J. Med.
Genet. B Neuropsychiatr. Genet.
153B, 1234–1239.
Diniz, M. G., Gomes, C. C., De Castro,
W. H., Guimaraes, A. L., De Paula,
A. M., Amm, H., et al. (2012). miR-
15a/16-1 influences BCL2 expres-
sion in keratocystic odontogenic
tumors. Cell Oncol. (Dordr.) 35,
285–291.
Dolken, L., Malterer, G., Erhard, F.,
Kothe, S., Friedel, C. C., Suffert, G.,
et al. (2010). Systematic analysis
of viral and cellular microRNA
targets in cells latently infected with
human gamma-herpesviruses
by RISC immunoprecipita-
tion assay. Cell Host Microbe 7,
324–334.
Domschke, K., Kuhlenbaumer, G.,
Schirmacher, A., Lorenzi, C.,
Armengol, L., Dibella, D., et al.
(2003). Human nuclear transcrip-
tion factor gene CREM: genomic
organization, mutation screening,
and association analysis in panic
disorder. Am. J. Med. Genet. B
Neuropsychiatr. Genet. 117B, 70–78.
Doxakis, E. (2010). Post-
transcriptional regulation of
alpha-synuclein expression by
mir-7 and mir-153. J. Biol. Chem.
285, 12726–12734.
Dweep, H., Sticht, C., Pandey, P.,
and Gretz, N. (2011). miRWalk–
database: prediction of possible
miRNA binding sites by "walk-
ing" the genes of three genomes.
J. Biomed. Inform. 44, 839–847.
Eddington, K. M., Dolcos, F., Cabeza,
R., Kr, R. K., and Strauman, T.
J. (2007). Neural correlates of
promotion and prevention goal
activation: an fMRI study using
an idiographic approach. J. Cogn.
Neurosci. 19, 1152–1162.
Edgar, R., Domrachev, M., and Lash,
A. E. (2002). Gene expression
omnibus: NCBI gene expression
and hybridization array data
repository. Nucleic Acids Res. 30,
207–210.
Fahn, S. (2011). Classification of move-
ment disorders. Mov. Disord. 26,
947–957.
Fahn, S., and Elton, R. (1987).
“Members of the updrs
Development Committee,” in
Recent Developments in Parkinson’s
Disease, Vol 2. eds S. Fahn, C.
D. Marsden, D. B. Calne, and
M. Goldstein (Florham Park,
NJ: Macmillan Health Care
Information), 153–163, 293–304.
Fimia, G. M., De Cesare, D., and
Sassone-Corsi, P. (2000). A family
of LIM-only transcriptional coac-
tivators: tissue-specific expression
and selective activation of CREB
and CREM. Mol. Cell. Biol. 20,
8613–8622.
Friedman, R. C., Farh, K. K., Burge, C.
B., and Bartel, D. P. (2009). Most
mammalian mRNAs are conserved
targets of microRNAs. Genome Res.
19, 92–105.
Garcia, J. M., Garcia, V., Pena, C.,
Dominguez, G., Silva, J., Diaz, R.,
et al. (2008). Extracellular plasma
RNA from colon cancer patients is
confined in a vesicle-like structure
and is mRNA-enriched. RNA 14,
1424–1432.
Gardina, P. J., Clark, T. A., Shimada,
B., Staples, M. K., Yang, Q., Veitch,
J., et al. (2006). Alternative splic-
ing and differential gene expres-
sion in colon cancer detected by
a whole genome exon array. BMC
Genomics 7:325. doi: 10.1186/1471-
2164-7-325
Gehrke, S., Imai, Y., Sokol, N., and




Goldman, J. G., and Litvan, I. (2011).
Mild cognitive impairment in
Parkinson’s disease. Minerva Med.
102, 441–459.
Graner, M. W., Alzate, O.,
Dechkovskaia, A. M., Keene, J.
D., Sampson, J. H., Mitchell, D.
A., et al. (2009). Proteomic and
immunologic analyses of brain
tumor exosomes. FASEB J. 23,
1541–1557.
Griffiths-Jones, S., Saini, H. K.,
Van Dongen, S., and Enright,
A. J. (2008). miRBase: tools for
microRNA genomics. Nucleic Acids
Res. 36, D154–D158.
Grigorian, A., Mkhikian, H., Li,
C. F., Newton, B. L., Zhou, R.
W., and Demetriou, M. (2012).
Pathogenesis of multiple sclerosis
via environmental and genetic
dysregulation of N-glycosylation.
Semin. Immunopathol. 34, 415–424.
Guil, S., and Caceres, J. F. (2007).
The multifunctional RNA-
binding protein hnRNP A1 is
required for processing of miR-
18a. Nat. Struct. Mol. Biol. 14,
591–596.
Guo, J., Miao, Y., Xiao, B., Huan,
R., Jiang, Z., Meng, D., et al.
(2008). Differential expression of
microRNA species in human gas-
tric cancer versus non-tumorous tis-
sues. J. Gastroenterol. Hepatol. 24,
652–657.
Guo, J., Miao, Y., Xiao, B., Huan,
R., Jiang, Z., Meng, D., et al.
(2009). Differential expression of
microRNA species in human gas-
tric cancer versus non-tumorous tis-
sues. J. Gastroenterol. Hepatol. 24,
652–657.
Hackl, M., Brunner, S., Fortschegger,
K., Schreiner, C., Micutkova, L.,
Mück, C., et al. (2010). miR-
17, miR-19b, miR-20a, and miR-
106a are down-regulated in human
aging. Aging Cell 9, 291–296.
Hafner, M., Landthaler, M., Burger,
L., Khorshid, M., Hausser, J.,
Berninger, P., et al. (2010).
Transcriptome-wide identifica-
tion of RNA-binding protein and
microRNA target sites by PAR-CLIP.
Cell 141, 129–141.
Han, S. P., Friend, L. R., Carson,
J. H., Korza, G., Barbarese, E.,
Maggipinto, M., et al. (2010).
Differential subcellular distribu-
tions and trafficking functions of
hnRNP A2/B1 spliceoforms. Traffic
11, 886–898.
Hardcastle, T. J., and Kelly, K. A.
(2010). baySeq: empirical Bayesian
methods for identifying differen-
tial expression in sequence count
data. BMC Bioinformatics 11:422.
doi: 10.1186/1471-2105-11-422
Hawkes, C. H., Del Tredici, K., and
Braak, H. (2010). A timeline for
Parkinson’s disease. Parkinsonism
Relat. Disord. 16, 79–84.
Heath, E., Sablitzky, F., and Morgan,
G. T. (2010). Subnuclear targeting
Frontiers in Molecular Neuroscience www.frontiersin.org May 2013 | Volume 6 | Article 10 | 18
Soreq et al. Parkinson leukocyte miRNA-splicing profiles
of the RNA-binding motif protein
RBM6 to splicing speckles and
nascent transcripts. Chromosome
Res. 18, 851–872.
Hébert, S. S., Horré, K., Nicolaï, L.,
Bergmans, B., Papadopoulou,
A. S., Delacourte, A., et al.
(2009). MicroRNA regulation
of Alzheimer’s Amyloid precursor
protein expression. Neurobiol. Dis.
33, 422–428.
Hosack, D. A., Dennis, G. Jr., Sherman,
B. T., Lane, H. C., and Lempicki,
R. A. (2003). Identifying biolog-
ical themes within lists of genes
with EASE.Genome Biol. 4:R70. doi:
10.1186/gb-2003-4-10-r70
Huang, G., Nishimoto, K., Zhou, Z.,
Hughes, D., and Kleinerman, E.
S. (2012). miR-20a encoded by
the miR-17-92 cluster increases
the metastatic potential of
osteosarcoma cells by regulat-
ing Fas expression. Cancer Res. 72,
908–916.
Irimia, M., and Blencowe, B. J. (2012).
Alternative splicing: decoding an
expansive regulatory layer. Curr.
Opin. Cell Biol. 24, 323–332.
Irizarry, R. A., Bolstad, B. M., Collin,
F., Cope, L. M., Hobbs, B., and
Speed, T. P. (2003). Summaries
of affymetrix GeneChip probe
level data. Nucleic Acids Res.
31, e15.
Johnson, R., Zuccato, C., Belyaev, N.
D., Guest, D. J., Cattaneo, E., and
Buckley, N. J. (2008). A microRNA-
based gene dysregulation pathway
in Huntington’s disease. Neurobiol.
Dis. 29, 438–445.
Kawaji, H., Nakamura, M., Takahashi,
Y., Sandelin, A., Katayama,
S., Fukuda, S., et al. (2008).
Hidden layers of human small
RNAs. BMC Genomics 9:157. doi:
10.1186/1471-2164-9-157
Kim, H. J., Kim, N. C., Wang, Y. D.,
Scarborough, E. A., Moore, J., Diaz,
Z., et al. (2013). Mutations in prion-
like domains in hnRNPA2B1 and
hnRNPA1 cause multisystem pro-
teinopathy and ALS. Nature 495,
467–473.
Kim, J., Inoue, K., Ishii, J., Vanti, W.
B., Voronov, S. V., Murchison, E.,
et al. (2007). A MicroRNA feedback
circuit in midbrain dopamine neu-
rons. Science 317, 1220–1224.
Kingwell, K. (2011). Parkinson dis-
ease. Constant-current deep
brain stimulation improves
symptoms in Parkinson dis-
ease. Nat. Rev. Neurol. 8:119. doi:
10.1038/nrneurol.2012.14
Konstantoulas, C. J., Parmar, M., and
Li, M. (2010). FoxP1 promotes mid-
brain identity in embryonic stem
cell-derived dopamine neurons by
regulating Pitx3. J. Neurochem. 113,
836–847.
Krichevsky, A. M., and Gabriely, G.
(2008). miR-21: a small multi-
faceted RNA. J. Cell. Mol. Med. 13,
39–53.
Lapuk, A., Marr, H., Jakkula, L., Pedro,
H., Bhattacharya, S., Purdom,
E., et al. (2010). Exon-level
microarray analyses identify
alternative splicing programs in
breast cancer. Mol. Cancer Res.
8, 961.
Lee, I., Ajay, S. S., Yook, J. I., Kim,
H. S., Hong, S. H., Kim, N.
H., et al. (2009). New class of
microRNA targets containing
simultaneous5′-UTR and 3′-UTR
interaction sites. Genome Res. 19,
1175–1183.
Lee, R. C., Feinbaum, R. L., and
Ambros, V. (1993). The, C. elegans
heterochronic gene lin-4 encodes
small RNAs with antisense com-
plementarity to lin-14. Cell 75,
843–854.
Lewis, B. P., Burge, C. B., and Bartel,
D. P. (2005). Conserved seed pair-
ing, often flanked by adenosines,
indicates that thousands of human
genes are microRNA targets. Cell
120, 15–20.
Li, J., Kong, X., Zhang, J., Luo, Q., Li,
X., and Fang, L. (2013). MiRNA-26b
inhibits proliferation by targeting
PTGS2 in breast cancer. Cancer Cell
Int. 13, 7.
Liu, J. P., Tang, Y., Zhou, S., Toh,
B. H., McLean, C., and Li, H.
(2010). Cholesterol involvement in
the pathogenesis of neurodegenera-
tive diseases. Mol. Cell. Neurosci. 43,
33–42.
Lonnstedt, I. S. T. (2002). Replicated
microarray data. Stat. Sinica 12,
31–46.
Lundstrom, K. (2011). Micro-RNA in
disease and gene therapy.Curr. Drug
Discov. Technol. 8, 76–86.
Maes, O. C., Chertkow, H. M., Wang,
E., and Schipper, H. M. (2009).
MicroRNA: implications for
Alzheimer disease and other human
CNS disorders. Curr. Genomics 10,
154–168.
Margis, R., and Rieder, C. R. (2011).
Identification of blood microRNAs
associated to Parkinsonis disease.
J. Biotechnol. 152, 96–101.
Martins, M., Rosa, A., Guedes, L.
C., Fonseca, B. V., Gotovac,
K., Violante, S., et al. (2011).
Convergence of miRNA expression
profiling, alpha-synuclein inter-
acton and GWAS in Parkinson’s
disease. PLoS ONE 6:e25443. doi:
10.1371/journal.pone.0025443
Mazumder, B., Seshadri, V., and Fox,
P. L. (2003). Translational control
by the 3′-UTR: the ends specify
the means. Trends Biochem. Sci. 28,
91–98.
Melas, P. A., Rogdaki, M., Osby, U.,
Schalling, M., Lavebratt, C., and
Ekstrom, T. J. (2012). Epigenetic
aberrations in leukocytes of patients
with schizophrenia: association
of global DNA methylation with
antipsychotic drug treatment
and disease onset. FASEB J. 26,
2712–2718.
Meshorer, E., Erb, C., Gazit, R.,
Pavlovsky, L., Kaufer, D., Friedman,
A., et al. (2002). Alternative splicing
and neuritic mRNA transloca-
tion under long-term neuronal
hypersensitivity. Science 295,
508–512.
Minones-Moyano, E., Porta, S.,
Escaramis, G., Rabionet, R., Iraola,
S., Kagerbauer, B., et al. (2011).
MicroRNA profiling of Parkinson’s
disease brains identifies early
downregulation of miR-34b/c
which modulate mitochondrial
function. Hum. Mol. Genet. 20,
3067–3078.
Mohamed, A. M., Boudreau, J. R.,
Yu, F. P., Liu, J., and Chin-Sang,
I. D. (2012). The Caenorhabditis
elegans Eph receptor activates
NCK and N-WASP, and inhibits
Ena/VASP to regulate growth cone
dynamics during axon guidance.
PLoS Genet. 8:e1002513. doi:
10.1371/journal.pgen.1002513
Moran, L. B., Duke, D. C., Deprez,
M., Dexter, D. T., Pearce, R. K.,
and Graeber, M. B. (2006). Whole
genome expression profiling of the
medial and lateral substantia nigra
in Parkinson’s disease. Neurogenetics
7, 1–11.
Mraz, M., Pospisilova, S., Malinova,
K., Slapak, I., and Mayer, J. (2009).
MicroRNAs in chronic lympho-
cytic leukemia pathogenesis and
disease subtypes. Leuk. Lymphoma
50, 506–509.
Niu, N., Rice, S. R., Heston, L. L.,
and Sobell, J. L. (2004). Multiple
missense mutations in the diazepam
binding inhibitor (DBI) gene iden-
tified in schizophrenia but lack of
disease association. Am. J. Med.
Genet. B Neuropsychiatr. Genet.
125B, 10–19.
Orom, U. A., Nielsen, F. C., and
Lund, A. H. (2008). MicroRNA-10a
binds the 5′UTR of ribosomal
protein mRNAs and enhances
their translation. Mol. Cell 30,
460–471.
Pan, Q., Shai, O., Lee, L. J., Frey, B. J.,
and Blencowe, B. J. (2008). Deep
surveying of alternative splicing
complexity in the human tran-
scriptome by high-throughput
sequencing. Nat. Genet. 40,
1413–1415.
Pang, M., Woodward, A. W.,
Agarwal, V., Guan, X., Ha, M.,
Ramachandran, V., et al. (2009).
Genome-wide analysis reveals rapid
and dynamic changes in miRNA
and siRNA sequence and expression
during ovule and fiber development
in allotetraploid cotton (Gossypium
hirsutum L.). Genome Biol
10, R122.
Perry, M. M., Moschos, S. A., Williams,
A. E., Shepherd, N. J., Larner-
Svensson, H. M., and Lindsay,
M. A. (2008). Rapid changes
in microRNA-146a expression
negatively regulate the IL-1beta-
induced inflammatory response in
human lung alveolar epithelial cells.
J. Immunol. 180, 5689–5698.
Pico, A. R., Kelder, T., Van Iersel, M.
P., Hanspers, K., Conklin, B. R.,
and Evelo, C. (2008). WikiPathways:
pathway editing for the people.
PLoS Biol. 6:e184. doi: 10.1371/jour-
nal.pbio.0060184
Pritchard, C. C., Cheng, H. H., and
Tewari, M. (2012). MicroRNA
profiling: approaches and con-
siderations. Nat. Rev. Genet. 13,
358–369.
Pu, X., Roth, J. A., Hildebrandt, M. A.,
Ye, Y., Wei, H., Minna, J. D., et al.
(2013). MicroRNA-related genetic
variants associated with clinical out-
comes in early stage non-small cell
lung cancer patients. Cancer Res. 73,
1867–1875.
Qiu, R., Wang, J., Tsark, W., and Lu,
Q. (2010). Essential role of PDZ-
RGS3 in the maintenance of neu-
ral progenitor cells. Stem Cells 28,
1602–1610.
Reinhart, B. J., Slack, F. J., Basson,
M., Pasquinelli, A. E., Bettinger,
J. C., Rougvie, A. E., et al. (2000).
The 21-nucleotide let-7 RNA reg-
ulates developmental timing in
Caenorhabditis elegans. Nature 403,
901–906.
Robinson, M. D., McCarthy, D. J., and
Smyth, G. K. (2010). edgeR: a bio-
conductor package for differential
expression analysis of digital gene
expression data. Bioinformatics 26,
139–140.
Robinson, M. D., and Oshlack, A.
(2010). A scaling normalization
method for differential expression
analysis of RNA-seq data. Genome
Biol. 11, R25.
Robinson, M. D., and Smyth, G.
K. (2008). Small-sample estima-
tion of negative binomial disper-
sion, with applications to SAGE
data. Biostatistics 9, 321–332.
Saba, R., Goodman, C. D., Huzarewich,
R. L. C. H., Robertson, C., and
Frontiers in Molecular Neuroscience www.frontiersin.org May 2013 | Volume 6 | Article 10 | 19
Soreq et al. Parkinson leukocyte miRNA-splicing profiles
Booth, S. A. (2008). A miRNA sig-
nature of prion induced neurode-
generation. PloS ONE 3:e3652. doi:
10.1371/journal.pone.0003652
Sakharkar, M. K., Chow, V. T.,
Chaturvedi, I., Mathura, V. S.,
Shapshak, P., and Kangueane,
P. (2004a). A report on single
exon genes (SEG) in eukaryotes.
Front. Biosci. 9:3262–3267. doi:
10.2741/1478
Sakharkar, M. K., Chow, V. T.,
and Kangueane, P. (2004b).
Distributions of exons and introns
in the human genome. In Silico Biol.
4, 387–393.
Salomonis, N., Nelson, B., Vranizan,
K., Pico, A. R., Hanspers, K.,
Kuchinsky, A., et al. (2009).
Alternative splicing in the differ-
entiation of human embryonic
stem cells into cardiac precursors.
PLoS Comput. Biol. 5:e1000553. doi:
10.1371/journal.pcbi.1000553
Salomonis, N., Schlieve, C. R., Pereira,
L., Wahlquist, C., Colas, A.,
Zambon, A. C., et al. (2010).
Alternative splicing regulates
mouse embryonic stem cell
pluripotency and differentiation.
Proc. Natl. Acad. Sci. U.S.A. 107,
10514–10519.
Sanborn, B. M., Millan, J. L., Meistrich,
M. L., and Moore, L. C. (1997).
Alternative splicing of CREB and
CREM mRNAs in an immortal-
ized germ cell line. J. Androl. 18,
62–70.
Satoh, J., and Tabunoki, H. (2011).
Comprehensive analysis of human
microRNA target networks.
BioData Min. 4, 17.
Scherzer, C. R., Eklund, A. C., Morse,
L. J., Liao, Z., Locascio, J. J., Fefer,
D., et al. (2007). Molecular mark-
ers of early Parkinson’s disease
based on gene expression in blood.
Proc. Natl. Acad. Sci. U.S.A. 104,
955–960.
Schopman, N. C., Heynen, S.,
Haasnoot, J., and Berkhout, B.
(2010). A miRNA-tRNA mix-up:
tRNA origin of proposed miRNA.
RNA Biol. 7, 573–576.
Smoot, M. E., Ono, K., Ruscheinski, J.,
Wang, P. L., and Ideker, T. (2011).
Cytoscape 2.8: new features for data
integration and network visualiza-
tion. Bioinformatics 27, 431–432.
Solmi, R., Ugolini, G., Rosati, G.,
Zanotti, S., Lauriola, M., Montroni,
I., et al. (2006). Microarray-
based identification and RT-PCR
test screening for epithelial-
specific mRNAs in peripheral
blood of patients with colon
cancer. BMC Cancer 6:250. doi:
10.1186/1471-2407-6-250
Soreq, L., Ben-Shaul, Y., Israel, Z.,
Bergman, H., and Soreq, H.
(2012a). Meta-analysis of genetic
and environmental Parkinson’s
disease models reveals a common
role of mitochondrial protection
pathways. Neurobiol. Dis. 45,
1018–1030.
Soreq, L., Bergman, H., Goll, Y.,
Greenberg, D. S., Israel, Z., and
Soreq, H. (2012b). Deep brain stim-
ulation induces rapidly reversible
transcript changes in Parkinson’s
leucocytes. J. Cell. Mol. Med. 16,
1496–1507.
Soreq, L., Bergman, H., Israel, Z.,
and Soreq, H. (2012c). Exon
arrays reveal alternative splicing
aberrations in Parkinson’s disease
leukocytes. Neurodegener. Dis. 10,
203–206.
Soreq, L., Israel, Z., Bergman, H.,
and Soreq, H. (2008). Advanced
microarray analysis highlights
modified neuro-immune signal-




Spinelli, S. V., Diaz, A., D’Attilio, L.,
Marchesini, M. M., Bogue, C.,
Bay, M. L., et al. (2013). Altered
microRNA expression levels in
mononuclear cells of patients
with pulmonary and pleural
tuberculosis and their relation
with components of the immune
response. Mol. Immunol. 53,
265–269.
Sugnet, C. W., Srinivasan, K., Clark, T.
A., O’Brien, G., Cline, M. S., Wang,
H., et al.. (2006). Unusual intron
conservation near tissue-regulated
exons found by splicing microar-
rays. PLoS Comput. Biol. 2:e4. doi:
10.1371/journal.pcbi.0020004
Ule, J., Jensen, K. B., Ruggiu, M.,
Mele, A., Ule, A., and Darnell, R.
B. (2003). CLIP identifies Nova-
regulated RNA networks in the
brain. Science 302, 1212–1215.
Vaarala, M. H., Hirvikoski, P.,
Kauppila, S., and Paavonen,
T. K. (2012). Identification of
androgen-regulated genes in
human prostate. Mol. Med. Rep. 6,
466–472.
Wang, P., Gu, Y., Zhang, Q., Han,
Y., Hou, J., Lin, L., et al. (2012).
Identification of resting and type
I IFN-activated human NK cell
miRNomes reveals MicroRNA-
378 and MicroRNA-30e as
negative regulators of NK cell
cytotoxicity. J. Immunol. 189,
211–221.
Xia, R., Jia, H., Fan, J., Liu, Y.,
and Jia, J. (2012). USP8 pro-
motes smoothened signaling by
preventing its ubiquitination and
changing its subcellular localiza-
tion. PLoS Biol. 10:e1001238. doi:
10.1371/journal.pbio.1001238
Zambon, A. C., Gaj, S., Ho, I.,
Hanspers, K., Vranizan, K., Evelo,
C. T., et al. (2012). GO-Elite: a
flexible solution for pathway and
ontology over-representation.
Bioinformatics 28, 2209–2210.
Zhang, H. G., and Grizzle, W. E.
(2011). Exosomes and cancer:
a newly described pathway of
immune suppression. Clin. Cancer
Res. 17, 959–964.
Conflict of Interest Statement: The
authors declare that the research
was conducted in the absence of any
commercial or financial relationships
that could be construed as a potential
conflict of interest.
Received: 07 March 2013; accepted: 16
April 2013; published online: 13 May
2013.
Citation: Soreq L, Salomonis N,
Bronstein M, Greenberg DS, Israel Z,
Bergman H and Soreq H (2013) Small
RNA sequencing-microarray analyses in
Parkinson leukocytes reveal deep brain
stimulation-induced splicing changes
that classify brain region transcriptomes.
Front. Mol. Neurosci. 6:10. doi: 10.3389/
fnmol.2013.00010
Copyright © 2013 Soreq, Salomonis,
Bronstein, Greenberg, Israel, Bergman
and Soreq. This is an open-access article
distributed under the terms of the
Creative Commons Attribution License,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are
credited and subject to any copyright
notices concerning any third-party
graphics etc.
Frontiers in Molecular Neuroscience www.frontiersin.org May 2013 | Volume 6 | Article 10 | 20
